Ascension Health Ventures joins as a new investor
Ivantis, a US-based eye disease company has raised $27m in its series B round from a consortium led by corporate venturing unit Ascension Health Ventures as a new investor.
Venture capital firms New Enterprise Associates (NEA) and Delphi Ventures, and MemorialCare Innovation Fund also participated in the round.
In June 2011, Ivantis raised $17m from NEA and Delphi, having been incubated at NEA in 2007.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
